Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • KU-55933: Potent and Selective ATM Kinase Inhibitor for D...

    2026-01-20

    KU-55933: Potent and Selective ATM Kinase Inhibitor for DNA Damage Response Studies

    Executive Summary: KU-55933 is a highly selective inhibitor of the ataxia-telangiectasia mutated (ATM) kinase, exhibiting an IC50 of 13 nM and a Ki of 2.2 nM in vitro (APExBIO). The compound preferentially inhibits ATM over structurally related kinases, such as DNA-PK, PI3K/PI4K, ATR, and mTOR. ATM kinase is pivotal in DNA damage response, particularly in phosphorylation events including Akt at Ser473, which is essential for cell survival signaling. KU-55933 blocks ATM-dependent phosphorylation, leading to G1 cell cycle arrest and decreased cyclin D1 levels. In cancer cell lines, it inhibits proliferation and alters cellular metabolism, increasing lactate production and glucose uptake while reducing ATP levels (Zhen et al., 2023).

    Biological Rationale

    ATM kinase is a serine/threonine protein kinase activated by DNA double-strand breaks (DSBs). It orchestrates the DNA damage response by phosphorylating downstream targets, including checkpoint proteins, p53, and Akt. ATM’s activity is crucial for maintaining genome integrity, regulating cell cycle checkpoints, and facilitating DNA repair. Aberrant ATM signaling is linked to ataxia-telangiectasia, a rare disorder characterized by genomic instability and cancer predisposition (Zhen et al., 2023). Selective ATM inhibition with KU-55933 enables precise dissection of these signaling cascades and is fundamental in cancer and DNA damage research workflows.

    Mechanism of Action of KU-55933 (ATM Kinase Inhibitor)

    KU-55933 competitively inhibits the ATP-binding site of ATM kinase, with an in vitro IC50 of 13 nM and Ki of 2.2 nM (APExBIO). Its selectivity over related kinases (e.g., DNA-PK, PI3K/PI4K, ATR, mTOR) has been demonstrated in kinase profiling assays, minimizing off-target effects (KU55933.com). ATM is required for the phosphorylation of downstream effectors such as p53 and Akt at Ser473; KU-55933 treatment abolishes these phosphorylation events in cellular assays. This inhibition disrupts cell survival and DNA repair pathways, leading to G1 cell cycle arrest by reducing cyclin D1 expression. The compound also induces metabolic changes, including increased glucose consumption and lactate production, and decreased ATP levels in MCF-7 cells.

    Evidence & Benchmarks

    • KU-55933 exhibits an in vitro IC50 of 13 nM and Ki of 2.2 nM for ATM kinase inhibition (APExBIO).
    • Selective inhibition over DNA-PK, PI3K/PI4K, ATR, and mTOR was confirmed in kinase selectivity panels (KU55933.com).
    • Cellular assays show ~50% proliferation inhibition at 10 μM in MDA-MB-453 and PC-3 cancer cell lines (APExBIO).
    • Induces G1 cell cycle arrest and reduces cyclin D1 expression in ATM-dependent manner (Zhen et al., 2023).
    • In MCF-7 cells, increases lactate production and glucose consumption while decreasing ATP levels upon treatment (Zhen et al., 2023).
    • KU-55933 is insoluble in water and ethanol but soluble in DMSO at ≥41.67 mg/mL with gentle warming (APExBIO).
    • For optimal stability, store the compound desiccated at -20°C; stock solutions in DMSO are stable for several months below -20°C (APExBIO).
    • ATM kinase is central to the DNA damage checkpoint signaling pathway, and its inhibition impairs DSB repair, providing a rationale for ATM-targeted cancer therapy (Zhen et al., 2023).

    Applications, Limits & Misconceptions

    KU-55933 is widely used in DNA damage response research, cell cycle regulation, apoptosis studies, and cancer biology. Its high selectivity allows precise modulation of ATM-mediated signaling without significant impact on related kinases. In cancer models, KU-55933 aids in dissecting the role of ATM in cell proliferation, cell cycle arrest, and metabolic adaptation. Recent research also suggests ATM inhibition may intersect with cGAS-STING pathways impacting genome stability and retrotransposition (Zhen et al., 2023). For a broader discussion of translational applications, see this comparative article, which extends beyond conventional cancer research to iPSC-based disease modeling.

    Common Pitfalls or Misconceptions

    • KU-55933 does not inhibit ATR, DNA-PK, or mTOR at concentrations selective for ATM; using it as a pan-PI3K inhibitor is inaccurate (APExBIO).
    • Not suitable for in vivo studies without pharmacokinetics validation; currently validated for in vitro/cellular assays.
    • KU-55933 is insoluble in water and ethanol; DMSO is required for dissolution with gentle warming (APExBIO).
    • Long-term storage of solutions at room temperature leads to degradation; always store stock solutions below -20°C.
    • Assuming ATM inhibition will universally potentiate DNA damage response is incorrect; cellular context and compensatory mechanisms may modulate outcomes (KU55933.com).

    Workflow Integration & Parameters

    KU-55933 (A4605) from APExBIO is typically used in research applications involving DNA damage checkpoint signaling, cancer cell cycle analysis, and metabolic profiling. Recommended working concentration ranges from 0.5–10 μM, with significant cellular effects observed at 10 μM in MDA-MB-453 and PC-3 cancer cell lines. Dissolve the compound in DMSO (≥41.67 mg/mL) using gentle warming. Avoid aqueous or ethanol solvents. For storage, keep the solid compound desiccated at -20°C; DMSO stock solutions are stable for several months below -20°C but should not be stored long-term at room temperature. For detailed handling protocols and advanced use cases, refer to this workflow article, which expands on experimental troubleshooting and advanced applications.

    For a direct product overview and ordering information, visit the KU-55933 (ATM Kinase Inhibitor) product page.

    Conclusion & Outlook

    KU-55933 remains a gold-standard tool compound for ATM kinase inhibition, offering unmatched selectivity and potency for DNA damage response research. Its robust performance enables precise dissection of ATM-mediated pathways in cancer and genome stability studies. Future research may expand its utility into areas such as aging, retrotransposition, and metabolic regulation, as suggested by recent work on cGAS and genome integrity (Zhen et al., 2023). For comprehensive overviews of the latest experimental advances and comparative tool analysis, see this benchmark review, which clarifies how KU-55933 distinguishes itself from other ATM/PI3K inhibitors in the field.